

Introduction to the Cholera Vaccine Session

Pablo Sanchez, MD

Chair, Cholera Vaccine Work Group

Advisory Committee on Immunization Practices

February 25, 2021

Cholera vaccine work group members and contributors

ACIP members

- Pablo Sanchez (chair)
- Matt Daley (member)

***Ex officio* members**

- Bill Alexander (NIH)
- Tina Mongeau (FDA)

CDC lead

- Jenn Collins (NCEZID/DFWED)

ACIP liaisons

- Carol Baker (IDSA)
- Elizabeth Barnett (ISTM)
- Adam Ratner (AAP)

Technical advisors

- Mike Brady
- Ed Ryan (Harvard)
- Mary Wilson (UCSF/Harvard)

CDC contributors

- Grace Appiah (NCEZID/DGMQ)
- Bruce Gutelius (NCEZID/DFWED)
- Eric Mintz (NCEZID/DFWED)
- Talia Pindyk (NCEZID/DFWED)
- John Su (NCEZID/DHQP)
- Farrell Tobolowsky (NCEZID/DFWED)

Background and purpose of the work group

- **June 2016:** ACIP recommended the cholera vaccine CVD 103-HgR (Vaxchora) for adult travelers (18–64 years old) from the United States to an area of active cholera transmission
- **March 2020:** Emergent BioSolutions filed a Biologics License Application (BLA) supplement with FDA to expand age range for Vaxchora to children and adolescents 2–17 years old
- **October 2020:** ACIP cholera vaccine work group formed
- **December 2020:** FDA approved Vaxchora BLA supplement

Policy topic under consideration by work group

- Should ACIP cholera vaccine recommendations be expanded to include children and adolescents 2–17 years old?

Today's agenda

- Background on cholera and CVD 103-HgR
 - Jennifer Collins, MD, MSc (CDC/NCEZID/DFWED)
- Immunogenicity and safety of CVD 103-HgR (Vaxchora)
 - James McCarty, MD (Stanford University, Emergent BioSolutions)
- Work group plans
 - Jennifer Collins, MD, MSc (CDC/NCEZID/DFWED)